OtologicPharmaceutics
Therapeutic Solutions for Hearing Health
Latest Press & Media
TINNITUS TOGETHER
Beginning January 15, 2024, our collaborators at the Hough Ear Institute (HEI) will be offering Tinnitus Together, the first peer-to-peer tinnitus support group in the State of Oklahoma. This no-cost support group will be led by a licensed professional counselor,...
Our mission
Otologic Pharmaceutics, Inc. (OPI) is a company committed to developing treatments for acute and chronic hearing loss to reduce the incidence and severity of permanent hearing disorders.
Our mission is to treat hearing loss.
Otologic Pharmaceutics, Inc. (OPI) is a company committed to developing treatments for acute and chronic hearing loss to reduce the incidence and severity of permanent hearing disorders.
OPI’s program NHPN-1010, an oral medication to treat acute hearing loss, has successfully completed a Phase I clinical trial. Initial research focuses on NHPN-1010 as a treatment for Noise Induced Hearing Loss. OPI’s program OPI-001, an innovative treatment for acute and chronic hearing loss through the regeneration of sensory hair cells, has been awarded a Congressionally Directed Medical Research Programs grant from the Department of Defense to fund further preclinical research and development.
Contact us
Email Us
ehamm@ascendbioventures.com
Our Location
840 Research Parkway
Suite 250
Oklahoma City, OK 73104